Demographic, baseline characteristics, and remission induction results of the study population
Characteristic . | Median (range) . | No. (%) . | CR (%) . | P . |
|---|---|---|---|---|
| Overall | 104 (100) | 87 (84) | ||
| LPA96 study | 30 (29) | 24 (80) | .72 | |
| LPA99 study | 74 (71) | 63 (85) | ||
| Age, y | 68 (60-83) | |||
| 60-70 y | 70 (67) | 62 (89) | .096 | |
| 71 y or older | 34 (33) | 25 (74) | ||
| Sex | ||||
| Male | 44 (42) | 32 (73) | .021 | |
| Female | 60 (58) | 55 (92) | ||
| WBC count, × 109/L | 1.5 (0.3-84.1) | |||
| Less than 3.5 | 72 (69) | 63 (88) | ||
| 3.5-10 | 11 (11) | 10 (91) | .12* | |
| 10-50 | 13 (12) | 9 (69) | ||
| 50 or higher | 8 (8) | 5 (63) | ||
| Hemoglobin level, g/dL | 9.8 (4-15.2) | |||
| Less than 10 | 60 (58) | 48 (80) | .36 | |
| 10 or higher | 44 (42) | 39 (89) | ||
| Platelet count, × 109/L | 27 (2-207) | |||
| Less than 40 | 62 (62) | 48 (77) | .076 | |
| 40 or higher | 41 (38) | 38 (93) | ||
| FAB subtype | ||||
| Typical | 84 (81) | 71 (85) | .88 | |
| Variant | 20 (19) | 16 (80) | ||
| PML/RARα (n = 89) | ||||
| BCR1/BCR2 | 54 (61) | 46 (85) | .82 | |
| BCR3 | 38 (39) | 33 (87) | ||
| Relapse risk group | ||||
| Low | 38 (37) | 36 (95) | ||
| Intermediate | 44 (43) | 36 (82) | .019 | |
| High | 21 (20) | 14 (67) |
Characteristic . | Median (range) . | No. (%) . | CR (%) . | P . |
|---|---|---|---|---|
| Overall | 104 (100) | 87 (84) | ||
| LPA96 study | 30 (29) | 24 (80) | .72 | |
| LPA99 study | 74 (71) | 63 (85) | ||
| Age, y | 68 (60-83) | |||
| 60-70 y | 70 (67) | 62 (89) | .096 | |
| 71 y or older | 34 (33) | 25 (74) | ||
| Sex | ||||
| Male | 44 (42) | 32 (73) | .021 | |
| Female | 60 (58) | 55 (92) | ||
| WBC count, × 109/L | 1.5 (0.3-84.1) | |||
| Less than 3.5 | 72 (69) | 63 (88) | ||
| 3.5-10 | 11 (11) | 10 (91) | .12* | |
| 10-50 | 13 (12) | 9 (69) | ||
| 50 or higher | 8 (8) | 5 (63) | ||
| Hemoglobin level, g/dL | 9.8 (4-15.2) | |||
| Less than 10 | 60 (58) | 48 (80) | .36 | |
| 10 or higher | 44 (42) | 39 (89) | ||
| Platelet count, × 109/L | 27 (2-207) | |||
| Less than 40 | 62 (62) | 48 (77) | .076 | |
| 40 or higher | 41 (38) | 38 (93) | ||
| FAB subtype | ||||
| Typical | 84 (81) | 71 (85) | .88 | |
| Variant | 20 (19) | 16 (80) | ||
| PML/RARα (n = 89) | ||||
| BCR1/BCR2 | 54 (61) | 46 (85) | .82 | |
| BCR3 | 38 (39) | 33 (87) | ||
| Relapse risk group | ||||
| Low | 38 (37) | 36 (95) | ||
| Intermediate | 44 (43) | 36 (82) | .019 | |
| High | 21 (20) | 14 (67) |
FAB indicates French-American-British; PML/RAR, promyelocytic leukemia/retinoic acid receptor.
Less than 10 versus equal to or more than 10 WBC × 109/L (P = .043).